Mirae Asset Global Investments Co. Ltd. Sells 21,491 Shares of Amgen Inc. $AMGN

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 570,400 shares of the medical research company’s stock after selling 21,491 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Amgen were worth $186,698,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMGN. Vanguard Group Inc. raised its holdings in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares during the last quarter. Capital International Investors raised its stake in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors raised its stake in Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors lifted its holdings in Amgen by 2.7% in the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after buying an additional 122,631 shares during the period. Finally, Invesco Ltd. boosted its position in Amgen by 6.6% during the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after acquiring an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $349.39 on Friday. The company has a market cap of $188.56 billion, a P/E ratio of 24.55, a PEG ratio of 3.28 and a beta of 0.47. The company has a fifty day simple moving average of $363.49 and a 200 day simple moving average of $336.75. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AMGN shares. Guggenheim lifted their price objective on Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a research report on Thursday, April 9th. Argus upped their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Oppenheimer set a $400.00 target price on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Barclays began coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $356.24.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.